AstraZeneca is continuing its strategy of outlicensing drugs outside its core areas selling offÂa midstage pipeline CrohnÂs disease drug to Allergan in a deal potentially worth more than $1.5 billion.In an effort to boost sales AstraZeneca AZ is focusing o...
↧